WHO WE ARE

A Recognized Leader in Healthcare-Only Investor Relations & Strategic Advisory

Employing a unique “outsourced in-house” partnership model, Kilmer Lucas designs and executes customized IR and PR programs for medical device, drug development, cell therapy, diagnostics and healthcare services companies.

We speak your language. Before coming together, our team amassed decades of in-house IR, agency PR, news reporting, scientific writing, digital marketing and Wall Street experience. So, we know how to talk to your stakeholders too. To us, that is a fundamental point of differentiation. It gives Kilmer Lucas insight into what is most important to each and every stakeholder.

Your program will be fully customized in close collaboration with your company’s senior management, focusing on four general components:

Your Story

Generating a compelling investment story that highlights your company’s growth opportunities and competitive advantages

Audience

Identifying the ideal audience(s) for your company’s story and developing audience access strategies

Relationships

Developing and managing relationships with the right sell-side “sponsors” to directly market your story to investors

BioTuesdays

Bringing your news directly to a large and targeted audience via BioTuesdays

6 REASONS

Why Kilmer Lucas

01

Healthcare-only
A strategic advisory firm with decades of industry experience.

02

Unique “inside-looking-out” Orientation

The value of an IR firm with the insight of the most well-developed in-house IR department.

03

Proven Track Record

More than $3.3 billion raised to-date via multiple IPOs, follow-ons, cross-listings and uplistings.

04

BioTuesdays

Access to thousands of investment community and industry subscribers.

05

Flexibility

Round-the-clock access to senior team members.

06

Value

Reducing our clients’ cost of capital.

Thought Leadership